WHITNEY LOVETT: Open Payments
NPI 1922637354 · FORSYTH, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$946 in 56 payments from 19 companies in 2025. Trend: 2023 $1,629 · 2024 $1,689 · 2025 $946
Food & beverage: $946
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $141 |
| Sumitomo Pharma America, Inc. | 15 | $138 |
| Lilly USA, LLC | 6 | $104 |
| AstraZeneca Pharmaceuticals LP | 5 | $94 |
| ABBVIE INC. | 3 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $83 |
| Astellas Pharma US Inc | 3 | $59 |
| Lundbeck LLC | 2 | $49 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
Products named: GEMTESA, MOUNJARO, Wegovy, TRINTELLIX, FARXIGA, REXULTI, VRAYLAR, Veozah.
Industry payments across GA — which companies pay providers there.
